Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients

Correction to: Serious adverse events and fatal adverse events associated with nivolumab... Zhao et al. Journal for ImmunoTherapy of Cancer (2019) 7:9 https://doi.org/10.1186/s40425-018-0487-7 CORRECTION Open Access Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients 1* 2* 3* Bin Zhao , Hong Zhao and Jiaxin Zhao Correction to: Journal for ImmunoTherapy of Cancer (2018) 6:101 Doi 10.1186/s40425-018-0421-z Following publication of the original article [1], the authors reported an error in their listed affiliations. In this Correction Dr. Jiaxin Zhao is related to two affiliations: 1. The Second Affiliated Hospital & Yuying Children’s Hospital, Wenzhou Medical University, Wenzhou, China. 3. The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China. The published apologizes for any inconvenience caused by this error. Received: 19 December 2018 Accepted: 19 December 2018 Reference 1. Zhao, et al. Journal for ImmunoTherapy of Cancer. 2018;6(101). https://doi.org/10.1186/s40425-018-0421-z. * Correspondence: doctorbinzhao@126.com; doctorhongzhao@126.com; doctorzhaojiaxin@163.com The Second Affiliated Hospital & Yuying Children’s Hospital, Wenzhou Medical University, Wenzhou, China The Third Affiliated Hospital of Harbin Medical University, Harbin, China The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China © The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal for ImmunoTherapy of Cancer Springer Journals

Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients

Loading next page...
 
/lp/springer-journals/correction-to-serious-adverse-events-and-fatal-adverse-events-cv4r0UxYhq
Publisher
Springer Journals
Copyright
Copyright © 2019 by The Author(s).
Subject
Medicine & Public Health; Oncology; Immunology
eISSN
2051-1426
DOI
10.1186/s40425-018-0487-7
Publisher site
See Article on Publisher Site

Abstract

Zhao et al. Journal for ImmunoTherapy of Cancer (2019) 7:9 https://doi.org/10.1186/s40425-018-0487-7 CORRECTION Open Access Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients 1* 2* 3* Bin Zhao , Hong Zhao and Jiaxin Zhao Correction to: Journal for ImmunoTherapy of Cancer (2018) 6:101 Doi 10.1186/s40425-018-0421-z Following publication of the original article [1], the authors reported an error in their listed affiliations. In this Correction Dr. Jiaxin Zhao is related to two affiliations: 1. The Second Affiliated Hospital & Yuying Children’s Hospital, Wenzhou Medical University, Wenzhou, China. 3. The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China. The published apologizes for any inconvenience caused by this error. Received: 19 December 2018 Accepted: 19 December 2018 Reference 1. Zhao, et al. Journal for ImmunoTherapy of Cancer. 2018;6(101). https://doi.org/10.1186/s40425-018-0421-z. * Correspondence: doctorbinzhao@126.com; doctorhongzhao@126.com; doctorzhaojiaxin@163.com The Second Affiliated Hospital & Yuying Children’s Hospital, Wenzhou Medical University, Wenzhou, China The Third Affiliated Hospital of Harbin Medical University, Harbin, China The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China © The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Journal

Journal for ImmunoTherapy of CancerSpringer Journals

Published: Jan 11, 2019

There are no references for this article.